<DOC>
	<DOCNO>NCT00682591</DOCNO>
	<brief_summary>Prospective , longitudinal multi-center study perform 15 participate substitution center Germany . Aims : - Primary objective : To compare impact different substitution drug ( methadone , buprenorphine , suboxone ) neurocognitive , emotional , quality-of-life-related tolerability opioid dependent patient HCV treatment . - Secondary objective : To investigate IFN therapy impairs efficacy ( respect e.g . retention rate , concomitant drug use particular neurocognitive function ) tolerability agonist maintenance treatment methadone , buprenorphine , suboxone</brief_summary>
	<brief_title>Evaluation Neurocognitive Performance Drug Substituted Patients Under Hepatitis C Therapy</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<criteria>Opioiddependent patient current stable agonist maintenance therapy ( least 6 month prior study enrolment ) methadone , buprenorphine , suboxone . Patients need infect chronic hepatitis C must indication therapy peginterferon alfa ribavirin . Patients inform write consent respect followup psychiatric side effect particular neurocognitive performance . Patients baseline monitoring emotional state neurocognitive performance . According SPC According legal requirement reg . drug substitution therapy ( BTMVV ) Insufficient knowledge German language cognitive impairment ( due indispensable application questionnaire TAP , Test Battery Attentional Performance ) . Age 18 year 65 year coinfections hepatitis B virus human immunodeficiency virus</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>hepatitis C</keyword>
	<keyword>drug substitution</keyword>
	<keyword>neurocognitive</keyword>
	<keyword>patient stable drug substitution therapy</keyword>
	<keyword>patient interferon-based antiviral therapy</keyword>
</DOC>